TRAVASOL 5.5% W/ ELECTROLYTES

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 5.5% W/ ELECTROLYTES (TRAVASOL 5.5% W/ ELECTROLYTES).

How it works

TRAVASOL 5.5% W/ ELECTROLYTES is a parenteral nutritional solution providing amino acids and electrolytes. Amino acids serve as substrates for protein synthesis, while electrolytes maintain osmotic balance and support cellular functions. The solution bypasses gastrointestinal absorption, directly entering the bloodstream.

What the body does with it

Metabolism	Amino acids undergo hepatic metabolism via transamination, deamination, and urea cycle; electrolytes are excreted renally or reabsorbed as needed.
Excretion	Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Half-life	2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Protein binding	Low (<5%); primarily albumin via limited binding to aromatic amino acids.
Volume of Distribution	0.3–0.4 L/kg; reflects distribution into extracellular fluid.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: immediate with infusion; rapid equilibration.
Duration of Action	4–6 hours post-infusion for nitrogen balance; dependent on metabolic demand.

Classification & Brands

Dosing & administration

Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.

Dosage form	INJECTABLE
Renal impairment	GFR 10-50 mL/min: reduce dose by 50%; GFR <10 mL/min: avoid or use with caution, consider essential amino acid formulation; monitor for azotemia.
Liver impairment	Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated due to risk of hepatic encephalopathy; use branched-chain amino acid formulations if indicated.
Pediatric use	Neonates and infants: 2-3 g amino acids/kg/day IV; children: 1.5-2.5 g/kg/day IV; adjust based on age, weight, and clinical status; maximum infusion rate 0.1 g/kg/hour.
Geriatric use	Start at lower end of adult dose (25 mL/kg/day) due to decreased renal function; monitor fluid and electrolyte balance closely; adjust for comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 5.5% W/ ELECTROLYTES (TRAVASOL 5.5% W/ ELECTROLYTES).

Breastfeeding	Travasol 5.5% w/ Electrolytes is considered compatible with breastfeeding. Amino acids and electrolytes are normal milk constituents; additional maternal infusion does not significantly elevate milk concentrations. M/P ratio: Not applicable; components are endogenous and tightly regulated. No reported adverse effects in nursing infants.
Teratogenic Risk	No evidence of teratogenicity in animal or human studies; however, intravenous amino acids may cause metabolic acidosis and electrolyte imbalances in the mother, potentially affecting fetal pH and growth. First trimester: No known structural teratogenic effects. Second/third trimester: Risk of fetal acidosis and electrolyte disturbances if maternal homeostasis is not maintained.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe electrolyte or acid-base imbalances","Azotemia (elevated blood urea nitrogen)","Anuria or severe renal impairment","Hepatic encephalopathy","Known hypersensitivity to any component"]

Clinical Precautions

Precautions

["Risk of fluid or solute overload leading to hypervolemia, congestive heart failure, or pulmonary edema","Electrolyte imbalances (e.g., hyperkalemia, hyponatremia)","Acid-base disturbances","Phlebitis or infection at the infusion site"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TRAVASOL 5.5% W/ ELECTROLYTES

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 5.5% W/ ELECTROLYTES (TRAVASOL 5.5% W/ ELECTROLYTES).

How it works

What the body does with it

Metabolism	Amino acids undergo hepatic metabolism via transamination, deamination, and urea cycle; electrolytes are excreted renally or reabsorbed as needed.
Excretion	Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Half-life	2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Protein binding	Low (<5%); primarily albumin via limited binding to aromatic amino acids.
Volume of Distribution	0.3–0.4 L/kg; reflects distribution into extracellular fluid.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: immediate with infusion; rapid equilibration.
Duration of Action	4–6 hours post-infusion for nitrogen balance; dependent on metabolic demand.

Classification & Brands

Dosing & administration

Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.

Dosage form	INJECTABLE
Renal impairment	GFR 10-50 mL/min: reduce dose by 50%; GFR <10 mL/min: avoid or use with caution, consider essential amino acid formulation; monitor for azotemia.
Liver impairment	Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated due to risk of hepatic encephalopathy; use branched-chain amino acid formulations if indicated.
Pediatric use	Neonates and infants: 2-3 g amino acids/kg/day IV; children: 1.5-2.5 g/kg/day IV; adjust based on age, weight, and clinical status; maximum infusion rate 0.1 g/kg/hour.
Geriatric use	Start at lower end of adult dose (25 mL/kg/day) due to decreased renal function; monitor fluid and electrolyte balance closely; adjust for comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 5.5% W/ ELECTROLYTES (TRAVASOL 5.5% W/ ELECTROLYTES).

Breastfeeding	Travasol 5.5% w/ Electrolytes is considered compatible with breastfeeding. Amino acids and electrolytes are normal milk constituents; additional maternal infusion does not significantly elevate milk concentrations. M/P ratio: Not applicable; components are endogenous and tightly regulated. No reported adverse effects in nursing infants.
Teratogenic Risk	No evidence of teratogenicity in animal or human studies; however, intravenous amino acids may cause metabolic acidosis and electrolyte imbalances in the mother, potentially affecting fetal pH and growth. First trimester: No known structural teratogenic effects. Second/third trimester: Risk of fetal acidosis and electrolyte disturbances if maternal homeostasis is not maintained.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe electrolyte or acid-base imbalances","Azotemia (elevated blood urea nitrogen)","Anuria or severe renal impairment","Hepatic encephalopathy","Known hypersensitivity to any component"]